Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Ending Cash Position: €3.45 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:FDY Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd FRA:FDY
69 GF Score
Price €0.26
GF Value €0.23
! 2 Warning Signs
View Full Analysis

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ending Cash Position?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co FRA:FDY 69 Ending Cash Position is €3.45 Mil as of Dec. 2025. GuruFocus rates FRA:FDY with a GF Score™ of 69/100 and a GF Value™ of €0.23. The stock has 2 warning signs investors should review.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Ending Cash Position for the quarter that ended in Dec. 2025 was €3.45 Mil.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's quarterly Ending Cash Position increased from Jun. 2025 (€0.00 Mil) to Sep. 2025 (€133.80 Mil) but then declined from Sep. 2025 (€133.80 Mil) to Dec. 2025 (€3.45 Mil).

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's annual Ending Cash Position declined from Dec. 2023 (€153.59 Mil) to Dec. 2024 (€138.55 Mil) but then increased from Dec. 2024 (€138.55 Mil) to Dec. 2025 (€139.09 Mil).

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ending Cash Position Related Terms

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ending Cash Position Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 167.97 174.58 153.59 138.55 139.09

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.24 2.33 0.00 133.80 3.45
FRA:FDY
69GF Score
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd FRA:FDY
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=128.076+11.009
=139.09

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.294+-0.847
=3.45

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €3.45 Mil mean?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a Ending Cash Position of €3.45 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Ending Cash Position too high?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Ending Cash Position is €3.45 Mil. Overall, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Ending Cash Position compare to ZTS?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Ending Cash Position of €3.45 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co and its competitors. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Ending Cash Position is €3.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock overvalued right now?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) has a current Ending Cash Position of €3.45 Mil. The stock's GF Value™ is €0.23, compared to a current price of €0.26 — trading 13.9% above its estimated fair value. The current Ending Cash Position is €3.45 Mil. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY), the current Ending Cash Position is €3.45 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (FRA:FDY) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co stock appears to be overvalued. The current stock price of €0.26 is trading 13.9% above its estimated GF Value™ of €0.23.

Key valuation signals for FRA:FDY:

  • Ending Cash Position: €3.45 Mil
  • GF Value™: €0.23 vs. price of €0.26 (13.9% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the FRA:FDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Business Description

Other Exchanges 01349:Hong Kong688505:China
Address 308 Cailun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
69GF Score

Get the complete analysis for FRA:FDY

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.26
Price
€0.23
GF Value